Blimark CH, Vangsted AJ, Klausen TW, et al. - Real-world evidence from the nationwide Swedish and Danish registries demonstrate inferior outcomes in subgroups of multiple myeloma (MM) patients despite the introduction and rapid implementation of new and better treatments.

• Main findings from research performed within the Swedish and Danish myeloma registries were summarized, and first line treatment data were reported for more than 10.000 MM patients from Denmark and Sweden between 2005-2018.

• Higher incidence of MM as well as higher median age at diagnosis were revealed in national registries vs results from referral centres, suggesting a more complete coverage.

• This implies that prognostic scoring systems and indices are required to be validated in e.g., SMM and high-risk MM in a real- world-population.

• Subgroups of patients with comorbidity, myeloma complications, and early relapse were described.

• These subgroups exhibit worse survival, require new treatment approaches, and are unlikely to be captured in randomized clinical trials with narrow inclusion and exclusion criteria.

• Important information on epidemiology and management of MM is afforded by national registries that include all MM patients.